Sugi Predict

Sugi Predict / Compounds / SCHEMBL136365

SCHEMBL136365

SCHEMBL136365

C=C1CN(C(=O)OC(C)(C)C)CC1O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 2/20 0.43
▸ USP2 O75604 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NAMPT P43490 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ CHRM1 P11229 1/20 0.39
▸ CHRM3 P20309 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ GPR119 Q8TDV5 3/20 0.38
▸ ESR2 Q92731 1/20 0.38
▸ RECQL P46063 1/20 0.37
▸ EPHX1 P07099 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ THRB P10828 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ PTPN2 P17706 1/20 0.37
▸ PTPN1 P18031 1/20 0.37
▸ PTPN6 P29350 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28296118 1.00 NR1H2 (0.43) NR1H2USP2SMN1; SMN2NAMPTCHRM2
SCHEMBL22468373 1.00 NR1H2 (0.43) NR1H2USP2SMN1; SMN2NAMPTCHRM2
SCHEMBL733742 0.84 USP2 (0.42) NR1H2USP2SMN1; SMN2HPGDGPR119
SCHEMBL734541 0.84 USP2 (0.42) NR1H2USP2SMN1; SMN2HPGDGPR119
SCHEMBL17081077 0.81 NR1H2 (0.44) NR1H2USP2SMN1; SMN2NAMPTCHRM2
SCHEMBL136257 0.81 NR1H2 (0.41) NR1H2USP2SMN1; SMN2NAMPTHPGD
SCHEMBL19230405 0.79 NR1H2 (0.42) NR1H2USP2SMN1; SMN2NAMPTCHRM2
SCHEMBL8260058 0.78 NR1H2 (0.39) NR1H2USP2SMN1; SMN2NAMPTHPGD
SCHEMBL10441374 0.77 GAA (0.43) NR1H2USP2SMN1; SMN2NAMPTHPGD
SCHEMBL28871320 0.76 GPR119 (0.38) NR1H2USP2SMN1; SMN2NAMPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230081390-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2023-03-16 — — US disclosed
CN-109952289-B TRPV4 antagonists 葛兰素史密斯克莱知识产权（第2 号）有限公司 2022-12-09 — — CN disclosed
CN-109790116-B TRPV4 antagonists 葛兰素史密斯克莱知识产权（第2 号）有限公司 2022-10-28 — — CN disclosed
US-11260049-B2 TRPV4 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2022-03-01 — — US disclosed
EP-3941922-A1 INHIBITORS OF RAF KINASES Kinnate Biopharma Inc. (US) 2022-01-26 — — EP disclosed
US-11229623-B2 TRPV4 antagonists GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2022-01-25 — — US disclosed
CN-113874381-A Inhibitors of RAF kinase 金耐特生物制药公司 2021-12-31 — — CN disclosed
US-20210299113-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2021-09-30 — — US disclosed
EP-3515887-B1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2021-07-07 — — EP disclosed
EP-3515888-B1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2021-03-31 — — EP disclosed
EP-3515887-A1 TRPV4 ANTAGONISTS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2019-07-31 — — EP disclosed
US-20190216774-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2019-07-18 — — US disclosed
CN-109790116-A TRPV4 antagonist 葛兰素史密斯克莱知识产权（第2 号）有限公司 2019-05-21 — — CN disclosed
WO-2018055526-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed
WO-2018055524-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2018-03-29 — — WO disclosed
EP-2590985-B1 NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS RECORDATI IRELAND LTD (IE) 2014-05-14 — — EP disclosed
US-8580962-B2 Spiroheterocyclic compounds as mGlu5 antagonists RECORDATI IRELAND LTD. (IT) 2013-11-12 — — US disclosed
EP-2590985-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS Recordati Ireland Limited (IE) 2013-05-15 — — EP disclosed
US-20120059015-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS RECORDATI IRELAND LTD. (IT) 2012-03-08 — — US disclosed
WO-2012004400-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11260049-B2 TRPV4 antagonists TRPV4, TRPV5, TRPV2 NR1H2 2504/4885USP2 4317/4885SMN1; SMN2 2991/4885
US-20210299113-A1 TRPV4 ANTAGONISTS TRPV4, TRPV5, TRPV2 NR1H2 2504/4885USP2 4317/4885SMN1; SMN2 2991/4885
US-20230081390-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF NR1H2 983/4885USP2 1597/4885SMN1; SMN2 3700/4885
US-11229623-B2 TRPV4 antagonists TRPV4, TRPV5, TRPV2 NR1H2 2504/4885USP2 4317/4885SMN1; SMN2 2991/4885
US-20120059015-A1 NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS GRM5, GPR65, GRIK5 NR1H2 391/4885USP2 2844/4885SMN1; SMN2 308/4885
US-20190216774-A1 TRPV4 ANTAGONISTS TRPV4, TRPV5, TRPV2 NR1H2 2504/4885USP2 4317/4885SMN1; SMN2 2991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.